Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
Chenchen WangZhenjun ZhaoYudong ZhaoJie ZhaoLei XiaQiang XiaPublished in: Communications biology (2024)
DNA damage repair (DDR) genes are known to be closely associated with the progression of Hepatocellular carcinoma (HCC). Here we report a unique cluster of "deletion-up" genes in HCC, which are accordantly overexpressed in HCC patients and predict the unfavorable prognosis. Binding motif analysis and further validation with ChIP-qPCR unveil that the AP-2α directly modulate the transcription of critical DNA repair genes including TOP2A, NUDT1, POLD1, and PARP1, which facilitates the sanitation of oxidized DNA lesions. Structural analysis and the following validation identify LEI110 as a potent AP-2α inhibitor. Together, we demonstrate that LEI110 stabilizes AP-2α and sensitizes HCC cells toward DNA-damaging reagents. Altogether, we identify AP-2α as a crucial transcription modulator in HCC and propose small-molecule inhibitors targeting AP-2α are a promising novel class of anticancer agents. Our study provides insights into the concept of macroscopic inhibition of DNA damage repair-related genes in cancer treatment.
Keyphrases
- dna damage
- dna repair
- transcription factor
- genome wide identification
- small molecule
- oxidative stress
- induced apoptosis
- genome wide
- dna binding
- end stage renal disease
- circulating tumor
- ejection fraction
- cell free
- newly diagnosed
- single molecule
- chronic kidney disease
- bioinformatics analysis
- dna methylation
- drinking water
- prognostic factors
- drug delivery
- anti inflammatory
- high throughput